open access

Vol 49, No 1 (2011)
Review paper
Published online: 2011-04-19
Submitted: 2011-12-19
Get Citation

Proteomics of M-phase entry: ‘Omen’ vs. ‘Omre’, the battle for oocyte quality and beyond

Jacek Z. Kubiak
DOI: 10.5603/FHC.2011.0001
·
Folia Histochem Cytobiol 2011;49(1):1-7.

open access

Vol 49, No 1 (2011)
REVIEW
Published online: 2011-04-19
Submitted: 2011-12-19

Abstract

The understanding of cell cycle regulation benefited greatly from omic approaches. Because the cell cycle engine relies heavily on proteins, proteomic methods play a key role in identification of cell cycle players. The proteomic approach delivers an enormous volume of data, but it often lacks comprehensiveness. To ensure the comprehensiveness of results the discovery of novel proteins must be followed by functional analysis. Using Xenopus laevis oocytes in two different proteomic screens, we have recently identified a number of proteins whose behavior suggested specific and unexpected roles in M-phase entry. Functional analysis of EP45 identified in one of these screens has shown that M-phase entry is stimulated by Oocyte-Maturation-ENhancer (‘Omen’) activity. The second screen suggests the presence of an antagonistic activity, which we call ‘Omre’ (Oocyte- -Maturation-REpressor). The equilibrium between Omen and Omre activities may determine the quality of oocytes and further embryo development via participation in making the decision whether to enter oocyte maturation. It remains an open question whether similar activities operate during mitotic divisions in embryonic and adult cells. Identifying such activities in somatic cells might impact on cancer treatments. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 1–7)

Abstract

The understanding of cell cycle regulation benefited greatly from omic approaches. Because the cell cycle engine relies heavily on proteins, proteomic methods play a key role in identification of cell cycle players. The proteomic approach delivers an enormous volume of data, but it often lacks comprehensiveness. To ensure the comprehensiveness of results the discovery of novel proteins must be followed by functional analysis. Using Xenopus laevis oocytes in two different proteomic screens, we have recently identified a number of proteins whose behavior suggested specific and unexpected roles in M-phase entry. Functional analysis of EP45 identified in one of these screens has shown that M-phase entry is stimulated by Oocyte-Maturation-ENhancer (‘Omen’) activity. The second screen suggests the presence of an antagonistic activity, which we call ‘Omre’ (Oocyte- -Maturation-REpressor). The equilibrium between Omen and Omre activities may determine the quality of oocytes and further embryo development via participation in making the decision whether to enter oocyte maturation. It remains an open question whether similar activities operate during mitotic divisions in embryonic and adult cells. Identifying such activities in somatic cells might impact on cancer treatments. (Folia Histochemica et Cytobiologica 2011, Vol. 49, No. 1, 1–7)
Get Citation

Keywords

Bet-hedging; cell cycle; EP45; M-phase entry; oocyte; proteomics; Xenopus laevis

About this article
Title

Proteomics of M-phase entry: ‘Omen’ vs. ‘Omre’, the battle for oocyte quality and beyond

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 1 (2011)

Article type

Review paper

Pages

1-7

Published online

2011-04-19

DOI

10.5603/FHC.2011.0001

Bibliographic record

Folia Histochem Cytobiol 2011;49(1):1-7.

Keywords

Bet-hedging
cell cycle
EP45
M-phase entry
oocyte
proteomics
Xenopus laevis

Authors

Jacek Z. Kubiak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl